{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:30:07Z","timestamp":1787941807765,"version":"build-2784847793"},"reference-count":37,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                    isolates (2,614) were collected from patients at 135 U.S. Medical Centers during 2014. Isolates were evaluated for multidrug resistance to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim\u2013sulfamethoxazole, and levofloxacin. A single isolate (853008) demonstrated a ceftaroline nonsusceptible minimal inhibitory concentration (MIC) value, and it was subjected to molecular characterization. Ceftaroline (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , \u22640.015\/0.12\u2009\u03bcg\/ml) was eightfold more potent than ceftriaxone (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , \u22640.06\/1\u2009\u03bcg\/ml) against all isolates. For multidrug-resistant (MDR) isolates (28.8% of tested strains), ceftaroline (MIC\n                    <jats:sub>50\/90,<\/jats:sub>\n                    0.06\/0.25\u2009\u03bcg\/ml; 99.9% susceptible) was the most active agent tested, being eightfold more active than ceftriaxone (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.25\/2\u2009\u03bcg\/ml; 81.5% susceptible at MIC, \u22641\u2009\u03bcg\/ml) and 16-fold more active than penicillin (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.25\/4\u2009\u03bcg\/ml; 78.5% susceptible at MIC, \u22642\u2009\u03bcg\/ml). Isolate 853008 was a single locus variant of sequence type 377 and serotype 35B. It had multiple substitutions in the penicillin-binding proteins (PBPs), mainly PBP2x, when compared with reference sequences from the R6 strain. Isolate 853008 showed 31 amino acid alterations in MurM. The\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    data presented here confirm that ceftaroline potency against\n                    <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic>\n                    to be higher than other \u03b2-lactams, including against those isolates demonstrating ceftriaxone nonsusceptible and MDR phenotypes.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2016.0258","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T16:36:10Z","timestamp":1480955770000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Ceftaroline Activity Against Multidrug-Resistant\n                    <i>Streptococcus pneumoniae<\/i>\n                    from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate"],"prefix":"10.1177","volume":"23","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories"},{"name":"University of Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,7]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.03.2130"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1128\/AAC.02976-14","article-title":"Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011\u20132012): ceftaroline remains active in vitro among beta-lactam agents","volume":"58","author":"Mendes R.E.","year":"2014","unstructured":"Mendes R.E., , Biek D., , Critchley I.A., , Farrell D.J., , Sader H.S., , and Jones R.N.. 2014. Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011\u20132012): ceftaroline remains active in vitro among beta-lactam agents. Antimicrob. Agents Chemother., 58:4923\u20134927.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.diagmicrobio.2012.08.024","article-title":"Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998\u20132011)","volume":"75","author":"Jones R.N.","year":"2013","unstructured":"Jones R.N., , Sader H.S., , Mendes R.E., , and Flamm R.K.. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998\u20132011). Diagn. Microbiol. Infect. Dis., 75:107\u2013109.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"3","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1093\/cid\/cis561","article-title":"AWARE ceftaroline surveillance program (2008\u20132010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller M.A.","year":"2012","unstructured":"Pfaller M.A., , Farrell D.J., , Sader H.S., , and Jones R.N.. 2012. AWARE ceftaroline surveillance program (2008\u20132010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin. Infect. Dis., 55 Suppl 3:S187\u2013S193.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter S.S.","year":"2014","unstructured":"Richter S.S., , Diekema D.J., , Heilmann K.P., , Dohrn C.L., , Riahi F., , and Doern G.V.. 2014. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob. Agents Chemother., 58:6484\u20136489.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cid\/cir326","article-title":"Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States","volume":"53","author":"Rosen J.B.","year":"2011","unstructured":"Rosen J.B., , Thomas A.R., , Lexau C.A., , Reingold A., , Hadler J.L., , Harrison L.H., , Bennett N.M., , Schaffner W., , Farley M.M., , Beall B.W., , Moore M.R.; CDC Emerging Infections Program Network. 2011. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin. Infect. Dis., 53:137\u2013143.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2014.05.020","article-title":"Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine","volume":"80","author":"Mendes R.E.","year":"2014","unstructured":"Mendes R.E., , Costello A.J., , Jacobs M.R., , Biek D., , Critchley I.A., , and Jones R.N.. 2014. Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagn. Microbiol. Infect. Dis., 80:19\u201325.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.02557-13","article-title":"Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers","volume":"58","author":"Flamm R.K.","year":"2014","unstructured":"Flamm R.K., , Sader H.S., , Farrell D.J., , and Jones R.N.. 2014. Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. Antimicrob. Agents Chemother., 58:2468\u20132471.","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"e_1_3_3_10_2","first-page":"iii45","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley I.A.","year":"2011","unstructured":"Critchley I.A., , Eckburg P.B., , Jandourek A., , Biek D., , Friedland H.D., , and Thye D.A.. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J. Antimicrob. Chemother., 66 Suppl 3:iii45\u2013iii51.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","article-title":"Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia","volume":"73","author":"Frampton J.E.","year":"2013","unstructured":"Frampton J.E. 2013. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs, 73:1067\u20131094.","journal-title":"Drugs"},{"issue":"3","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008\u20132010)","volume":"55","author":"Farrell D.J.","year":"2012","unstructured":"Farrell D.J., , Castanheira M., , Mendes R.E., , Sader H.S., , and Jones R.N.. 2012. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008\u20132010). Clin. Infect. Dis., 55 Suppl 3:S206\u2013S214.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program","volume":"56","author":"Flamm R.K.","year":"2012","unstructured":"Flamm R.K., , Sader H.S., , Farrell D.J., , and Jones R.N.. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob. Agents Chemother., 56:2933\u20132940.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diagmicrobio.2013.08.027","article-title":"Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009\u20132011)","volume":"78","author":"Pfaller M.A.","year":"2014","unstructured":"Pfaller M.A., , Flamm R.K., , Sader H.S., , and Jones R.N.. 2014. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009\u20132011). Diagn. Microbiol. Infect. Dis., 78:422\u2013428.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1128\/AAC.04614-14","article-title":"Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program","volume":"59","author":"Sader H.S.","year":"2015","unstructured":"Sader H.S., , Flamm R.K., , Streit J., , Farrell D.J., , and Jones R.N.. 2015. Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob. Agents Chemother., 59:2458\u20132461.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-10"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae","volume":"53","author":"McGee L.","year":"2009","unstructured":"McGee L., , Biek D., , Ge Y., , Klugman M., , du Plessis M., , Smith A.M., , Beall B., , Whitney C.G., , and Klugman K.P.. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents. Chemother., 53:552\u2013556.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_3_18_2","unstructured":"Teflaro\u00ae Package Insert. 2013. Forest Laboratories Inc. New York City NY."},{"key":"e_1_3_3_19_2","unstructured":"Zinforo\u00ae. 2015. Zinforo\u00ae Product Information."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/INF.0000000000000307","article-title":"Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012)","volume":"33","author":"Sader H.S.","year":"2014","unstructured":"Sader H.S., , Mendes R.E., , Farrell D.J., , Flamm R.K., , and Jones R.N.. 2014. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012). Pediatr. Infect. Dis. J., 33:837\u2013842.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1128\/AAC.02794-15","article-title":"Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014","volume":"60","author":"Sader H.S.","year":"2016","unstructured":"Sader H.S., , Flamm R.K., , Mendes R.E., , Farrell D.J., , and Jones R.N.. 2016. Antimicrobial activities of ceftaroline and comparator agents against bacterial organisms causing bacteremia in patients with skin and skin structure infections in U.S. Medical Centers, 2008 to 2014. Antimicrob. Agents. Chemother., 60:2558\u20132563.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_3_22_2","unstructured":"CLSI. 2015. M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_23_2","unstructured":"CLSI. 2016. M100-S26. Performance Standards for Antimicrobial Susceptibility Testing: 26th Informational Supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1128\/AAC.00182-15","article-title":"Non-invasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States (2009\u20132012)","volume":"59","author":"Mendes R.E.","year":"2015","unstructured":"Mendes R.E., , Hollingsworth R.C., , Costello A., , Jones R.N., , Isturiz R.E., , Hewlett D.Jr., , and Farrell D.J.. 2015. Non-invasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States (2009\u20132012). Antimicrob. Agents Chemother., 59:5595\u20135601.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-595"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.7.2565-2571.2001"},{"key":"e_1_3_3_27_2","volume":"22","author":"Metcalf B.J.","unstructured":"Metcalf B.J., , Gertz R.E.Jr., , Gladstone R.A., , Walker H., , Sherwood L.K., , Jackson D., , Li Z., , Law C., , Hawkins P.A., , Chochua S., , Sheth M., , Rayamajhi N., , Bentley S. D., , Kim L., , Whitney C.G., , McGee L., , Beall B.; Active Bacterial Core surveillance team. 2016. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin. Microbiol. Infect., 22:60.e69\u201360.e29.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/595857","article-title":"Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004\u20132005","volume":"48","author":"Richter S.S.","year":"2009","unstructured":"Richter S.S., , Heilmann K.P., , Dohrn C.L., , Riahi F., , Beekmann S.E., , and Doern G.V.. 2009. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004\u20132005. Clin. Infect. Dis., 48: e23\u2013e33.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1093\/jac\/dkv061","article-title":"Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011\u20132013","volume":"70","author":"Golden A.R.","year":"2015","unstructured":"Golden A.R., , Adam H.J., , Gilmour M.W., , Baxter M.R., , Martin I., , Nichol K.A., , Demczuk W.H., , Hoban D.J., , and Zhanel G.G.. 2015. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011\u20132013. J. Antimicrob. Chemother., 70:1960\u20131964.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2217\/fmb.12.2","article-title":"Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae","volume":"7","author":"Hakenbeck R.","year":"2012","unstructured":"Hakenbeck R., , Bruckner R., , Denapaite D., , and Maurer P.. 2012. Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae. Future Microbiol., 7:395\u2013410.","journal-title":"Future Microbiol."},{"key":"e_1_3_3_31_2","first-page":"e000756","article-title":"Penicillin-binding protein transpeptidase signatures for tracking and predicting beta-lactam resistance levels in Streptococcus pneumoniae","volume":"7","author":"Li Y.","year":"2016","unstructured":"Li Y., , Metcalf B.J., , Chochua S., , Li Z., , Gertz R.E.Jr., , Walker H., , Hawkins P.A., , Tran T., , Whitney C.G., , McGee L., , and Beall B.W.. 2016. Penicillin-binding protein transpeptidase signatures for tracking and predicting beta-lactam resistance levels in Streptococcus pneumoniae. MBio., 7:e000756\u2013000716.","journal-title":"MBio."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1306"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.48.10.4020-4022.2004","article-title":"Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs","volume":"48","author":"Kosowska K.","year":"2004","unstructured":"Kosowska K., , Jacobs M.R., , Bajaksouzian S., , Koeth L., , and Appelbaum P.C.. 2004. Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs. Antimicrob. Agents. Chemother., 48:4020\u20134022.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2393-2396.2001"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/AAC.00590-10","article-title":"Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin","volume":"54","author":"Davies T.A.","year":"2010","unstructured":"Davies T.A., , He W., , Bush K., , and Flamm R.K.. 2010. Affinity of ceftobiprole for penicillin-binding protein 2b in Streptococcus pneumoniae strains with various susceptibilities to penicillin. Antimicrob. Agents. Chemother., 54:4510\u20134512.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00029-07"},{"key":"e_1_3_3_37_2","article-title":"Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs","author":"Lahiri S.D.","year":"2016","unstructured":"Lahiri S.D., , and Alm R.A.. 2016. Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs. J. Antimicrob. Chemother. [Epub ahead of print] DOI: 10.1093\/jac\/dkw282","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_38_2","unstructured":"Tygacil\u00ae. 2014. Wyeth Pharmaceuticals Philadelphia PA."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2016.0258","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0258","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:31:16Z","timestamp":1777667476000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2016.0258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1089\/mdr.2016.0258"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2016.0258","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}